For patients I see in clinic, retatrutide may potentially be a highly impactful future tool to treat their obesity and transform their health trajectory. Commenting on the topline results, Professor Graham Finlayson, chair in psychobiology at the University of Leeds, said it was striking to see retatrutide reaching the weight loss range historically associated with bariatric surgery and that the headline efficacy results are impressive, particularly the proportion of participants reported to achieve very large weight losses. He added: In principle, that broader pharmacology could produce larger effects on body weight and metabolism, although the full peer-reviewed data will be needed to understand the balance between efficacy, tolerability and discontinuation. While this clinical trial did not examine weight regain after stopping retatrutide, other studies have found that discontinuing weight-loss medications such as semaglutide and liraglutide typically results in near-total weight regain within about 18 months

Cost comparison: semaglutide vs
439 Liquid biopsy provides a dynamic window for monitoring tumor resistance, but its clinical application faces four major bottlenecks
pediatric trials ran 612 months [1]
Well monitor your progress through regular follow-up appointments and make any necessary dose adjustments, and provide ongoing support to address questions or concerns